Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05UHF
|
|||
| Former ID |
DAP001290
|
|||
| Drug Name |
Galsulfase
|
|||
| Synonyms |
Aryplase; Aryplase (TN); Galsulfase (genetical recombination); Galsulfase (USAN/INN); Galsulfase (genetical recombination) (JAN)
Click to Show/Hide
|
|||
| Indication | Mucopolysaccharidosis [ICD-11: 5C56.3; ICD-9: 277.5] | Approved | [1] | |
| Therapeutic Class |
Enzyme Replacement Agents
|
|||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D01001 | |||
| SuperDrug ATC ID |
A16AB08
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-acetylgalactosamine-4-sulfatase (G4S) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme ) therapy. J Inherit Metab Dis. 2013 Mar;36(2):385-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.